Neogap Therapeutics Selected for EIC Soft-landing Programme in Boston

Neogap Therapeutics, a Swedish biotech company developing personalized immunotherapy for cancer treatment, has been selected to participate in the EIC Soft-landing Programme for Healthcare and Life Sciences in Boston, USA. The program is organized by the European Innovation Council (EIC) and aims to support growth companies with research-driven technology and international expansion potential.

The EIC Soft-landing Programme offers business development support and opportunities to establish contacts with investors, academic environments, and life science players in Boston – a global hub for cancer research and biotechnology. Neogap’s combination of AI, bioinformatics, and cell biology in the development of personalized immunotherapy aligns well with the program’s focus on technologically advanced companies.

The program is part of the European Innovation Council’s Business Acceleration Services and brings together selected companies from across the EIC’s network. Neogap has previously received funding through the EIC Accelerator and is now participating in the Soft-landing Programme as part of the company’s international establishment strategy.

“Being selected for the EIC Soft-landing Programme is confirmation that our technology has great relevance in international innovation contexts. The program gives us a concrete opportunity to strengthen our presence in the American market and build new relationships,” says Samuel Svensson, CEO of Neogap Therapeutics.

The program includes a preparation phase during the spring and concludes with an intensive week in Boston on June 9–13, 2025, when Neogap will present its technology to investors and potential partners and participate in networking activities with selected European companies.

Neogap is developing pTTL, a personalized cell-based immunotherapy that enhances the patient’s own T-cells to fight solid tumors. The treatment is based on the company’s patented PIOR® and EpiTCer® technologies and is currently in a clinical phase I/II study for advanced colorectal cancer.

Project reference number: 190185439 – NEOpTTL. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EISMEA. Neither the European Union nor the granting authority can be held responsible for them.

For more information, please contact:
Samuel Svensson, CEO 
Phone: +46 733 54 21 94
E-mail: samuel.svensson@neogap.se

About Neogap Therapeutics
Neogap Therapeutics is a Swedish biotech company in clinical phase developing a personalized immunotherapy for the treatment of cancer using the patient’s own cells. The therapy is based on the company’s two technologies PIOR® and EpiTCer®. PIOR® is an advanced software that uses DNA sequencing data from the patient and machine learning to select tumor-specific mutations. EpiTCer® is then used to propagate the T-cells that can recognize the selected tumor-specific target structures. Neogap is located at Cancercentrum Karolinska in Stockholm. For more information about Neogap and its innovative research, visit neogap.se and follow Neogap on LinkedIn.

---

Enjoyed this post by Thibault Helle? Subscribe for more insights and updates straight from the source.